A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Corvus goes pivotal in peripheral T-cell lymphoma
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
